Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam RNAi 2010 Program Calls For Four New Business Partnerships

This article was originally published in The Pink Sheet Daily

Executive Summary

Company also is targeting four new RNAi projects in clinical development by the end of 2010.

You may also be interested in...



Alnylam Strengthens IP Position With Acquisition Of Nucleonics Patent Estate

RNAi-focused biotech calls acquisition inexpensive, will prevent potential end-around of its intellectual property.

Alnylam Strengthens IP Position With Acquisition Of Nucleonics Patent Estate

RNAi-focused biotech calls acquisition inexpensive, will prevent potential end-around of its intellectual property.

Publication Of Regulus Preclinical Study Derisks Micro RNA Therapeutics

Article in Nature reports anti-miR-21 compound prevents heart failure in mouse model.

Related Content

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel